Skip to content

Cipropofol anaesthesia on postoperative liver function and quality of recovery in patients undergoing partial hepatectomy

Cipropofol anaesthesia on postoperative liver function and quality of recovery in patients undergoing partial hepatectomy: one randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093457
Enrollment
Unknown
Registered
2024-12-05
Start date
2024-12-25
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Diseases

Interventions

Ciprofol group:Intravenous pumping of ciprofol during maintenance of anesthesia
Sevoflurane group:Inhaled sevoflurane during anesthesia maintenance

Sponsors

Xiangya Hospital Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Subjects scheduled for partial hepatectomy; 2. Age 18 to 65 years old, gender is not limited; 3. American Society of Anesthesiologists (ASA) class I, II, III; 4. Body mass index (BMI) of 18-28 kg/m^2 ; 5. The patient's cognitive status is good; 6. Voluntary participation and signed informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with Child-Pugh score grading B or C, hepatic encephalopathy, ascites or ruptured varices of the esophagogastric fundus with bleeding, prothrombin time >16 seconds, International Normalized Ratio (INR) >1.5, Activated Partial Thromboplastin Time (APTT) >36 seconds, Prothrombin Time (PT) >18 seconds, Platelet Count (PC) <100*10^9/L; 2.Patients with severe organ dysfunction such as heart, lung, brain, kidney and other severe pathologies; 3.Patients with cognitive impairment or history of psychiatric disorders, etc., who are unable to cooperate with the investigators; 4.Long-term use of sedative or analgesic drugs, opioid dependence or tolerance, and history of drug abuse; 5.History of allergy or contraindication to the anesthetic drugs used; 6.Have motion sickness or previous history of postoperative nausea and vomiting (PONV); 7.Patients who have been determined to have difficulty with airway management; 8.Any other condition that, in the opinion of the investigator, makes participation in this trial inappropriate.

Design outcomes

Primary

MeasureTime frame
the level of Alanine aminotransferase in serum;the level ofAspartate aminotransferase in serum;Total serum protein level;Serum albumin levelxue;Serum total bilirubin level;Dosage of perioperative vasoactive drugs;Perioperative Adverse Time Occurrence;

Secondary

MeasureTime frame
Perioperative hemodynamic ;Indicators for monitoring depth of perioperative anesthesia (EEG bispectral index);Dosage of perioperative anesthetic drugs;Serum inflammatory markers (interleukin 6, tumor necrosis factor alpha);Quality of recovery three days after surgery (qor-15 scale score);

Countries

China

Contacts

Public ContactHui Luo

Xiangya Hospital Central South University

huiluo@csu.edu.cn+86 137 8741 2956

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026